Kineta Operating Expenses 2014-2024 | KANT
Kineta operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Kineta Annual Operating Expenses
(Millions of US $) |
| 2023 |
$21 |
| 2022 |
$43 |
| 2021 |
$20 |
| 2020 |
$63 |
| 2019 |
$30 |
| 2018 |
$66 |
| 2017 |
$65 |
| 2016 |
$46 |
| 2015 |
$29 |
| 2014 |
$21 |
| 2013 |
$17 |
Kineta Quarterly Operating Expenses
(Millions of US $) |
| 2024-06-30 |
$3 |
| 2024-03-31 |
$6 |
| 2023-12-31 |
$4 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$6 |
| 2023-03-31 |
$7 |
| 2022-12-31 |
$27 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$6 |
| 2022-03-31 |
$6 |
| 2021-12-31 |
$-16 |
| 2021-09-30 |
$11 |
| 2021-06-30 |
$12 |
| 2021-03-31 |
$13 |
| 2020-12-31 |
$40 |
| 2020-09-30 |
$9 |
| 2020-06-30 |
$7 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$-24 |
| 2019-09-30 |
$13 |
| 2019-06-30 |
$21 |
| 2019-03-31 |
$20 |
| 2018-12-31 |
$17 |
| 2018-09-30 |
$20 |
| 2018-06-30 |
$17 |
| 2018-03-31 |
$12 |
| 2017-12-31 |
$15 |
| 2017-09-30 |
$16 |
| 2017-06-30 |
$18 |
| 2017-03-31 |
$16 |
| 2016-12-31 |
$14 |
| 2016-09-30 |
$12 |
| 2016-06-30 |
$11 |
| 2016-03-31 |
$9 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$8 |
| 2015-06-30 |
$8 |
| 2015-03-31 |
$6 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
